Pharmaceutical giant Bristol-Myers Squibb (NYSE: BMY) announced Tuesday that it is acquiring RayzeBio (NASDAQ: RYZB) for $4.1 billion, strengthening its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE